Brokerages predict that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will report sales of $1.21 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $2.30 million. The business is scheduled to issue its next earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Karyopharm Therapeutics will report full year sales of $31.07 million for the current fiscal year, with estimates ranging from $29.89 million to $34.65 million. For the next fiscal year, analysts anticipate that the firm will report sales of $23.67 million, with estimates ranging from $8.88 million to $45.98 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Karyopharm Therapeutics.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.21. The firm had revenue of $19.89 million for the quarter, compared to analysts’ expectations of $5.97 million.

Several brokerages have weighed in on KPTI. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 29th. Robert W. Baird reaffirmed a “buy” rating and set a $25.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. Finally, BidaskClub downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.90.

In other news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 18th. The shares were sold at an average price of $18.27, for a total value of $182,700.00. Following the transaction, the chief executive officer now owns 512,144 shares of the company’s stock, valued at $9,356,870.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $18.72, for a total transaction of $234,000.00. Following the completion of the transaction, the insider now directly owns 726,010 shares in the company, valued at approximately $13,590,907.20. The disclosure for this sale can be found here. Insiders have sold 1,056,701 shares of company stock worth $20,901,401 in the last ninety days. Insiders own 13.26% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 24.3% in the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after buying an additional 3,653 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Karyopharm Therapeutics by 38.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after buying an additional 4,556 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Karyopharm Therapeutics by 16.3% in the first quarter. Wells Fargo & Company MN now owns 36,036 shares of the company’s stock worth $483,000 after buying an additional 5,062 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Karyopharm Therapeutics by 23.6% in the first quarter. New York State Common Retirement Fund now owns 37,700 shares of the company’s stock worth $506,000 after buying an additional 7,200 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Karyopharm Therapeutics by 12.8% in the first quarter. Swiss National Bank now owns 64,150 shares of the company’s stock worth $861,000 after buying an additional 7,300 shares in the last quarter. 71.40% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:KPTI traded down $0.92 during trading hours on Friday, hitting $17.17. 244,700 shares of the stock traded hands, compared to its average volume of 576,829. Karyopharm Therapeutics has a 1 year low of $9.00 and a 1 year high of $21.71. The company has a market capitalization of $1.11 billion, a P/E ratio of -6.38 and a beta of 3.72.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Featured Article: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.